BrainsWay Doubles Down on Neurolief with $6M Investment After FDA Nod
Event summary
- BrainsWay invested an additional $6M in Neurolief following FDA approval of Proliv™Rx for MDD.
- Total investment in Neurolief now stands at $11M, with potential for another $5M tranche.
- BrainsWay holds a call option to acquire Neurolief, with valuation tied to revenue milestones.
- Neurolief's Proliv™Rx is the first at-home neurostimulation device for treatment-resistant MDD.
- Neurolief secured VA health system access via Federal Supply Schedule inclusion.
The big picture
BrainsWay's investment reflects a strategic bet on complementary neurostimulation technologies, expanding its reach beyond clinic-based treatments. The FDA approval of Proliv™Rx validates at-home neurostimulation as a viable treatment option for MDD, potentially reshaping the mental health treatment landscape. With $17M in total potential investment, BrainsWay is positioning itself for either a long-term partnership or full acquisition of Neurolief, depending on commercial success.
What we're watching
- Market Expansion
- How Neurolief's at-home solution will affect BrainsWay's clinic-based Deep TMS market share.
- Regulatory Momentum
- Whether FDA approval will accelerate commercial adoption of Proliv™Rx in the VA system.
- Execution Risk
- The pace at which Neurolief can scale operations to meet revenue-based investment triggers.
Related topics